InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos

InflaRx is assessing the feasibility of broadening its European strategy for ANCA-associated vasculitis (AAV) following the EMA's recommendation to revoke marketing authorization for competitor drug Tavneos. The company plans to engage with regulators regarding both vilobelimab and izicopan to determine the most efficient development path for these C5a/C5aR inhibitors in the AAV indication.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.